Primary sclerosing cholangitis

Digestive Diseases

Volumn 32, Issue 4, 2014, Pages 438-445

  Williamson, Kate D ^a,b   Chapman, Roger W ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cholangiocarcinoma; Cholestasis; Inflammatory bowel disease; Primary sclerosing cholangitis

Indexed keywords

URSODEOXYCHOLIC ACID; BILIRUBIN; COLESEVELAM; COLESTYRAMINE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; MERCAPTOPURINE; METHOTREXATE; NALTREXONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RIFAMPICIN;

ARTICLE; BILE DUCT CARCINOMA; CHOLESTASIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; HEREDITY; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; OSTEOPOROSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SEROLOGY; ABDOMINAL PAIN; BILIRUBIN BLOOD LEVEL; CHOLANGIOGRAPHY; CHOLANGITIS; COLORECTAL CANCER; CROHN DISEASE; DECOMPENSATED LIVER CIRRHOSIS; ENVIRONMENTAL FACTOR; FATIGUE; FEVER; GALLBLADDER CANCER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HEPATOMEGALY; JAUNDICE; LETHARGY; LIVER CELL CARCINOMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGOR; SEX DIFFERENCE; SEX RATIO; SMOKING; SPLENOMEGALY; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION; CHOLANGITIS, SCLEROSING; COMPLICATION; PATHOLOGY;

CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS;

EID: 84903464649     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000358150     Document Type: Article

References (54)

1. Hoffman CEE: Verschluss der Gallenwege durch Verdickung der Wandungen. Arch Pathol Anat Physiol 1867; 39: 206-215.
2. Broome U, Olsson R, Loof L, et al: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615.
3. Williamson KD, Chapman RW: Primary sclerosing cholangitis; in Warrell DA, Cox T, Firth J (eds): Oxford Textbook of Medicine, ed 5 (electronic resource). Oxford, Oxford University Press, 2010 (updated Nov 2012), chapt 15.21.4.
4. Ngu JH, Gearry RB, Wright AJ, et al: Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 1092-1097; quiz e135.
5. Boonstra K, Beuers U, Ponsioen CY: Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012; 56: 1181-1188.
6. Lindkvist B, Benito de Valle M, Gullberg B, et al: Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010; 52: 571-577.
7. Mitchell SA, Thyssen M, Orchard TR, et al: Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut 2002; 51: 567-573.
8. van Erpecum KJ, Smits SJ, van de Meeberg PC, et al: Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology 1996; 110: 1503-1506.
9. Loftus EV Jr., Sandborn WJ, Tremaine WJ, et al: Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology 1996; 110: 1496-1502.
10. Melum E, Franke A, Schramm C, et al: Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43: 17-19.
11. Liu JZ, Hov JR, Folseraas T, et al: Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013; 45: 670-675.
12. Hirschfield GM, Karlsen TH, Lindor KD, et al: Primary sclerosing cholangitis. Lancet 2013; 382: 1587-1599.
13. Alswat K, Al-Harthy N, Mazrani W, et al: The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012; 107: 56-63.
14. Bjornsson E, Chari S, Silveira M, et al: Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011; 18: 198-205.
15. Mendes FD, Jorgensen R, Keach J, et al: Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-2075.
16. Parhizkar B, Mohammad Alizadeh AH, Asad zadeh Aghdaee H, et al: Primary sclerosing cholangitis associated with elevated immunoglobulin-G4: a preliminary study. ISRN Gastroenterol 2012; 2012: 325743.
17. Alderlieste YA, van den Elzen BD, Rauws EA, et al: Immunoglobulin G4-Associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009; 79: 220-228.
18. O'Toole A, Alakkari A, Keegan D, et al: Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 439-441.
19. Schrumpf E, Elgjo K, Fausa O, et al: Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689-697.
20. Olsson R, Danielsson A, Jarnerot G, et al: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-1323.
21. Loftus EV Jr., Harewood GC, Loftus CG, et al: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96.
22. Sano H, Nakazawa T, Ando T, et al: Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011; 18: 154-161.
23. Boonstra K, van Erpecum KJ, van Nieuwkerk KM, et al: Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2270-2276.
24. Halliday JS, Djordjevic J, Lust M, et al: A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 2012; 6: 174-181.
25. Marelli L, Xirouchakis E, Kalambokis G, et al: Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-1228.
26. Moncrief KJ, Savu A, Ma MM, et al: The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation-A single-centre experience. Can J Gastroenterol 2010; 24: 40-46.
27. Papatheodoridis GV, Hamilton M, Mistry PK, et al: Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-644.
28. Jorgensen KK, Grzyb K, Lundin KE, et al: Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012; 18: 536-545.
29. Angulo P, Grandison GA, Fong DG, et al: Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011; 140: 180-188.
30. Campbell MS, Lichtenstein GR, Rhim AD, et al: Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int 2005; 25: 311-316.
31. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
32. Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50(suppl 1):i1-i9.
33. Boonstra K, Weersma RK, van Erpecum KJ, et al: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055.
34. Bergquist A, Ekbom A, Olsson R, et al: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327.
35. Al Mamari S, Djordjevic J, Halliday JS, et al: Improvement of serum alkaline phosphatase to 36Lindstrom L, Hultcrantz R, Boberg KM, et al:Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.Clin Gastroenterol Hepatol2013;11:841-846
36. Lindstrom L, Hultcrantz R, Boberg KM, et al: Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11: 841-846.
37. Broome U, Lofberg R, Veress B, et al: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408.
38. Soetikno RM, Lin OS, Heidenreich PA, et al: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-Analysis. Gastrointest Endosc 2002; 56: 48-54.
39. Jess T, Simonsen J, Jorgensen KT, et al: Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381.e1.
40. Lindstrom L, Lapidus A, Ost A, et al: Increased risk of colorectal cancer and dysplasia in patients with Crohn's colitis and primary sclerosing cholangitis. Dis Colon Rectum 2011; 54: 1392-1397.
41. Braden B, Halliday J, Aryasingha S, et al: Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2012; 10: 303-308.
42. Chapman R, Fevery J, Kalloo A, et al: Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678.
43. Jorgensen KK, Lindstrom L, Cvancarova M, et al: Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012; 47: 1021-1029.
44. Fevery J, Verslype C, Lai G, et al: Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3123-3135.
45. Boberg KM, Bergquist A, Mitchell S, et al: Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-1211.
46. Moreno Luna LE, Kipp B, Halling KC, et al: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131: 1064-1072.
47. Darwish Murad S, Kim WR, Harnois DM, et al: Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.e3; quiz e14.
48. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-695.
49. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsoy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzen H, Ung KA, Eriksson A, Loof L, Prytz H, Marschall HU, Broome U: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-1472.
50. Lindor KD, Kowdley KV, Luketic VA, et al: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814.
51. Ashraf I, Choudhary A, Arif M, et al: Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-Analysis. Indian J Gastroenterol 2012; 31: 69-74.
52. Lindstrom L, Boberg KM, Wikman O, et al: High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012; 35: 451-457.
53. Fosby B, Karlsen TH, Melum E: Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1-15.
54. Vera A, Moledina S, Gunson B, et al: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 1943-1944.